Measuring Our Impact

When women can access affordable contraception, they can live their best and fullest lives. As part of our pioneering non-profit pharmaceutical business model, Medicines360 makes its product available at a  price substantially below the 340B ceiling price set by statute to clinics participating in the 340B Drug Pricing Program. A key component of measuring our impact is determining how this price affects equity, access, and cost.

Since April 2015, more than 220,000 units of our product have been distributed to 340B-enrolled clinics. Here’s what we know about the impact of those units:

  • Medicines360 is improving equity in the marketplace: Women who use our product are twice as likely to be uninsured as users of other products in the same product category.*
  • Medicines360 is enabling access: An independent study published by Roth et al. retrospectively looked at electronic health records from seven Title X clinics in Utah.** These sites reported that, after introducing Medicines360’s product, the percentage of patients choosing any of the products in the same product category increased.
  • Medicines360 is creating cost savings for the public health system: We estimate that, by offering our product at a price substantially below the 340B ceiling price set by statute to qualifying public health centers in the U.S., we’ve saved the health system more than $57 million.***

Moving forward, we’re undertaking new activities to measure our impact and identify remaining challenges to access. Here’s what we’re working on:

  • In fall 2019, we distributed a nationwide survey to public sector clinics purchasing products using 340B pricing. We designed the survey to help understand how price affects the patients these clinics serve. For example, we asked clinics using our product whether it had enabled them to lower out-of-pocket costs for patients, increased their monthly number of product administrations, or expanded their range of services. We also asked clinics about challenges they still face.
  • Our team has been conducting in-depth interviews with providers and administrators at clinics and networks offering our product. These interviewees provide insightful qualitative data that complement survey responses.
  • Finally, we’ll be releasing data from a longitudinal study of public health centers that adopted our product. Specifically, this analysis looks at the change in likelihood that an uninsured woman would receive a product in our product category before and after their clinic introduced our product.
  • Medicines360 is proud of our work to date, including the more than 220,000 units of our product that have been used by public health clinics. In part, our impact measurement work assesses how these units have affected clinics and the women they serve.

However, there is much work left to do. Our impact measurement helps us work towards closing the equity gap moving forward. Stay tuned as we learn and share more!

* Data on file. Medicines360: San Francisco, CA.
** Roth LP, Sanders JN, Simmons RG, et al. Contraception. 2018 July;98(1):63-68.
*** Data on file. Medicines360: San Francisco, CA.

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit medicines360.org

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.